Researchers at Montreal's Clinical Research Institute identified a new class of plant-derived molecules that block Ebola and SARS-CoV-2 up to 25 times more effectively than existing treatments. The team screened natural compounds and found these molecules disrupt viral replication with remarkable potency.
The discovery addresses a pressing need. Pandemic threats continue to emerge, and current antiviral options remain limited. Natural products have historically yielded important drugs, from aspirin to antimalarial compounds. These new molecules represent another avenue for rapid therapeutic development when outbreaks occur.
The researchers plan next steps: further testing in animal models and eventual clinical trials. They will also investigate how these compounds work at the molecular level to optimize their effectiveness and reduce side effects. The team hopes to understand which plant sources yield the most powerful variants, potentially accelerating drug development pipelines during future health crises.
This work demonstrates why screening biodiversity matters for medicine. As viruses mutate and new pathogens emerge, nature's chemical arsenal offers solutions that synthetic chemistry alone cannot match. The Institute continues searching for additional antiviral compounds from natural sources, recognizing that the next pandemic may require tools we discover today.